氨氯地平/阿托伐他汀治疗高血压合并高脂血症的疗效观察

目的 前瞻性评估氨氯地平/阿托伐他汀(多达一)治疗原发性高血压合并高脂血症的疗效和安全性.方法 102 例轻、中度原发性高血压合并高脂血症患者服用多达一1～2 片,共12 周.服药前、后行动态血压监测(ABPM),颈动脉内膜厚度和血脂测定,观察降压效果、不良反应、颈动脉内膜厚度和血脂的变化.结果 多达一能有效降低血压,12 周治疗的有效率为74%.颈动脉粥样斑块平均厚度由(2.03±0.25)mm下降为(1.57±0.21)mm,下降幅度为23%;TC 由(6.19±0.40)mmol/L 下降为(4.39±0.37)mmol/L,下降幅度为29%;LDL-C 由(4.19±0.35)mmol/L 下降为(2.98±0.31)mmol/L,下降幅度为24%;HDL-C 由(1.04±0.23)mmol/L 上升为(1.28±0.26)mmol/L,上升幅度为18%(P＜0.01).多达一不良反应发生率低.结论 多达一能有效控制血压和降低胆固醇,是强化抗动脉粥样硬化的降压药,能提供更多心脑血管保护.

The effects of amlodipine/atorvastatin for patients with concomitant mild to moderate hypertension and hyperlipidaemia

Objective The purpose of this study is to investigate the safety and effectively protective effects of the single-pill （amlodipine/atorvastatin） intake among patients with concomitant mild to moderate hypertension and hyperllpidaemia. Methods A total of 102 subjects were recruited in the study, and all of them were patients with mild to moderate hypertension and hyperlipidaemia. During a period of 12 weeks, each of them was given one to two pills （amlodipine/atorvastatin） per day. At the end of 12 weeks, the protective effects of the pill （amlodipine/atorvastatin） were evaluated in each subject by ABPM and carotid intima-media tnickness measurement. In addition, we assessed the adverse effects of the pill on each individual. Results In general, both SBP and DBP decreased after treatment, with an effective rate of 74%. Mean carotid intima-media thickness decreased from （2.03＋0.25）mm to （1.57＋0.21）mm （-23%）. TC decreased from （6.19＋0.40）mmol/L to （4.39＋ 0.37）mmol/L （29%）. Similarly, LDL-C was reduced from （4.19±0.35）mmol/L to （2.98±0.31）mmo1/L（24%）. HDL-C, however, increased from （1.04±0.23）mmol/L to （1.28±0.26）mmol/L （18%, P〈0.01）. Therefore, the adverse effects of the pill on patients are unapparent or acceptable. Conclusion The study indicates that oral medication of amlodipine/atorvastatinomle （one to two tables per day） was practically effective in patients withhypertension and hyperlipidaemia. Furthermore, the atorvastatinomle has anti-atherogenic effect but also increased risk of cardiovascular events. results of our study not only suggests that amlodipine/ indicates that it may provide greater protection against the